Patents by Inventor Scott L. Dax

Scott L. Dax has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR
    Publication number: 20080300236
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Application
    Filed: July 16, 2008
    Publication date: December 4, 2008
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • COLD MENTHOL RECEPTOR-1 ANTAGONISTS
    Publication number: 20080287398
    Abstract: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.
    Type: Application
    Filed: May 2, 2008
    Publication date: November 20, 2008
    Inventors: Raymond W. Colburn, Scott L. Dax, Christopher Flores, Jay Matthews
  • Tricyclic ?- opioid modulators
    Patent number: 7439239
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases and conditions, including pain. Such compounds are represented by Formula I as follows: wherein A, G, Y, R3-R5 are defined herein.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: October 21, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Steve Coats, Scott L. Dax, Bart DeCorte, Li Liu, Mark McDonnell, James J. McNally
  • Piperdinyl-phenoxazine and phenothiazine derivatives as ?-opioid modulators
    Patent number: 7432257
    Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: October 7, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Steve J. Coats, Scott L. Dax, Bart DeCorte, Li Liu, Mark McDonnell, James J. McNally
  • NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS
    Publication number: 20080132540
    Abstract: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.
    Type: Application
    Filed: November 19, 2007
    Publication date: June 5, 2008
    Inventors: Nicholas I. Carruthers, Wenying Chai, Scott L. Dax, Jill A. Jablonowski, Xiaobing Li, Timothy W. Lovenberg, William V. Murray, Dale A. Rudolph, Mark Seierstad, Mark A. Youngman
  • Non-peptidic NPY Y2 receptor inhibitors
    Patent number: 7317025
    Abstract: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: January 8, 2008
    Assignee: Johnson & Johnson Pharmaceutical Research & Development, LLC
    Inventors: Nicholas I. Carruthers, Wenying Chai, Scott L. Dax, Jill A. Jablonowski, Xiaobing Li, Timothy W. Lovenberg, William V. Murray, Dale A. Rudolph, Mark Seierstad, Mark A. Youngman
  • Benzimidazole Modulators of VR1
    Publication number: 20070259936
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: April 13, 2007
    Publication date: November 8, 2007
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Weils, Derek A. Beauchamp
  • Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor
    Patent number: 7183411
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: February 27, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
    Patent number: 7071195
    Abstract: Amine and amide derivatives of the formula: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing amines and amides of formula A as the active ingredient are described. The amines and amides of formula A are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: July 4, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Scott L. Dax, James McNally, Mark Youngman
  • Aminotetralin-derived urea modulators of vanilloid VR1 receptor
    Patent number: 6984647
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to ?-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: January 10, 2006
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Quinoline-derived amide modulators of vanilloid VR1 receptor
    Publication number: 20040192728
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Application
    Filed: February 2, 2004
    Publication date: September 30, 2004
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor
    Publication number: 20040157865
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Application
    Filed: July 10, 2003
    Publication date: August 12, 2004
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Aminotetralin-derived urea modulators of vanilloid VR1 receptor
    Publication number: 20030236280
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to &bgr;-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Application
    Filed: May 15, 2003
    Publication date: December 25, 2003
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Amino pyrazole derivatives useful for the treatment of obesity and other disorders
    Patent number: 6531478
    Abstract: Amino pyrazole derivatives of the formula: which are ligands for the neuropeptide Y, subtype 5 receptor and pharmaceutical compositions containing an amino pyrazole derivative as the active ingredient are described. The amino pyrazole derivatives are useful in the treatment of disorders and diseases associated with the NPY receptor subtype Y5.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: March 11, 2003
    Inventors: Cheryl P. Kordik, Scott L. Dax, Chi Luo, Allen B. Reitz, James J. McNally, Timothy W. Lovenberg
  • Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
    Publication number: 20020115715
    Abstract: Amine and amide derivatives of the formula: 1
    Type: Application
    Filed: February 7, 2002
    Publication date: August 22, 2002
    Inventors: Scott L. Dax, James McNally, Mark Youngman
  • Amino pyrazole derivatives useful for the treatment of obesity and other disorders
    Publication number: 20020065289
    Abstract: Amino pyrazole derivatives of the formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: May 30, 2002
    Inventors: Cheryl P. Kordik, Scott L. Dax, Chi Luo, Allen B. Reitz, James J. McNally, Timothy W. Lovenberg
  • Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
    Patent number: 6380224
    Abstract: Amine and amide derivatives of the formula: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing amines and amides of formula A as the active ingredient are described. The amines and amides of formula A are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: April 30, 2002
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Scott L. Dax, James McNally, Mark Youngman
  • N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
    Patent number: 6201025
    Abstract: &bgr;-Aminotetralin derivatives of the formula: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a &bgr;-aminotetralin derivative as the active ingredient are described. The 62 -aminotetralins are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.
    Type: Grant
    Filed: October 6, 1999
    Date of Patent: March 13, 2001
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Scott L. Dax, Timothy W. Lovenberg, Ellen W. Baxter, John R. Carson, Donald W. Ludovici, Mark A. Youngman
  • N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
    Patent number: 6140354
    Abstract: .beta.-Aminotetralin derivatives of the formula: ##STR1## which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a .beta.-aminotetralin derivative as the active ingredient are described. The .beta.-aminotetralins are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: October 31, 2000
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Scott L. Dax, Timothy W. Lovenberg, James McNally, Allen B. Reitz, Mark A. Youngman